Figures computed from official regulatory filings — .
Analysttarget 54.71 USD (+79%) · consensus 5/5 · 7 buy · 0 hold · 0 sell
Ownershipinsiders 38.83% · institutions 40.75% · short 6.7% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for vTv Therapeutics Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
95 buys1 sell— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LPtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) |
| Al-Marzooqi Fahed | AwardD (derivative) | $210.5K | Unusual size | SEC |
| AKKARAJU SRINIVAStrack record | AwardD (derivative) | $210.5K | SEC |
| Phillips Anne M. | AwardD (derivative) | $210.5K | Unusual size | SEC |
| SPIEGELMAN DANIEL K | AwardD (derivative) | $210.5K | Unusual size | SEC |
| BAKER BROS. ADVISORS LPtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Tung Michael Stephen | AwardD (derivative) | $1.7M | SEC |
| SEKHRI PAUL Jtrack record | AwardD (derivative) | $5.2M | Unusual size | SEC |
| AKKARAJU SRINIVAStrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| AKKARAJU SRINIVAStrack record | Award | $1.6M | SEC |
| AKKARAJU SRINIVAStrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| BAKER JULIANtrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| BAKER JULIANtrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| BAKER JULIANtrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| AKKARAJU SRINIVAStrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| AKKARAJU SRINIVAStrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| BAKER JULIANtrack record | Award | n/a (No price was disclosed in the filing) | SEC |
| BAKER JULIANtrack record | Award | n/a (No price was disclosed in the filing) | SEC |
| BAKER JULIANtrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| BAKER FELIXtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Al-Marzooqi Fahed | AwardD (derivative) | $66.4K | SEC |
| Phillips Anne M. | AwardD (derivative) | $66.4K | Unusual size | SEC |
| AKKARAJU SRINIVAStrack record | AwardD (derivative) | $66.4K | SEC |
| BAKER FELIXtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SPIEGELMAN DANIEL K | AwardD (derivative) | $66.4K | Unusual size | SEC |